BioSpace News Archive

Genetown

Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression

The company is working to break into the broader depression market with SAGE-217. The company discussed its pipeline at its “FutureCast.”

July 25, 2019
·
3 min read
·
Mark Terry
Drug Development

Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations

FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial

July 25, 2019
·
4 min read
Deals

Gimv and other shareholders sell biopharmaceutical company Breath Therapeutics to Zambon after a fast development

Gimv, Sofinnova and Gilde Healthcare announced the sale of biopharmaceutical company Breath Therapeutics.

July 25, 2019
·
4 min read
Drug Development

Evotec SE: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough

Evotec SE announced that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough.

July 25, 2019
·
1 min read
Business

Strong clinical progress in H1 and transformative collaboration with Gilead announced

Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.

July 25, 2019
·
8 min read
FDA

FDA Approves First Needle-Free Glucagon to Treat Severe Hypoglycemia

It is the first and only nasally-dosed glucagon, which is indicated for diabetic patients undergoing a severe drop in blood sugar. Previously it was only administered by a complicated injection system.

July 25, 2019
·
2 min read
·
Mark Terry
Biotech Bay

Research Roundup: A Cell Type that Can Heal Cardiac Tissue and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

July 25, 2019
·
4 min read
·
Mark Terry
Business

Avalon GloboCare and GE Healthcare Partner to Advance Cellular Therapies

The deal is designed to accelerate Avalon’s standardization, automation and bio-production for CAR-T cells and other cellular therapies related to immunotherapy.

July 25, 2019
·
5 min read
·
Mark Terry
Business

Merck Keeps Expansions Rolling with New N.C. Manufacturing Site

Merck will invest $680 million to build a manufacturing facility in Durham and expand an existing site in Wilson.

July 25, 2019
·
2 min read
·
Alex Keown
Drug Development

CelGro® pre-clinical study validates high quality nerve repair

CelGro® Human Nerve Regeneration Trial Recently Orthocell announced that the first four patients successfully completed participation in the CelGro® nerve regeneration clinical trial.

July 25, 2019
·
6 min read